Compare The Coca-Cola Co K (KO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs ResMed Inc. — how do they compare? The Coca-Cola Co K trades at $82.05 (market cap $353.32B), while ResMed Inc. trades at $195.48 (market cap $28.81B). The key difference: The Coca-Cola Co K is far larger — about 12.3× ResMed Inc.'s market cap, and The Coca-Cola Co K pays the higher dividend (2.58%). Which is the better fit depends on your goals.
| KO | RMD | |
|---|---|---|
Market Cap | $353.32B | $28.81B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $84.92 | $293.73 |
52-Week Low | $65.67 | $182.82 |
Enterprise Value | $383.39B | $27.99B |
Dividend Yield | 2.58% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $82.08, up 0.64% on the day, with a bullish analyst consensus and strong earnings beats in recent quarters. The stock shows robust profitability with a 27.8% net margin and 45.8% ROE, though valuations like a P/E of 25.82 are elevated. Technicals are mixed with a bearish overall signal but support near $82. Recent news highlights institutional buying and stable demand trends ahead of Q2 earnings.
Outlook remains positive given consistent dividend growth, earnings outperformance, and a $90.67 price target. Risks include high debt levels and regional demand volatility. The stock offers stability for income investors but faces valuation pressures amid macroeconomic uncertainty.
ResMed (RMD) trades at $198.61, down 0.19% on the day, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals, with Q1 2026 EPS beating estimates at $2.86 and revenue growth from $5.15B in 2025 to a projected $5.5B in 2026. Recent news highlights the sale of its MatrixCare business for $490 million, sharpening focus on core sleep and respiratory care markets. Analyst consensus is a Buy with a $245.88 price target, implying significant upside.
The outlook for RMD is positive, driven by consistent earnings beats, robust cash flow growth, and strategic divestitures. Key opportunities include market leadership in sleep apnea and digital health innovation. Risks involve competitive pressures from GLP-1 drugs and macroeconomic headwinds. Institutional sentiment is mixed but leans bullish on long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
